Use of specialty care versus standard retail pharmacies for treatment of hepatitis C

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 202-209

  Cohen, Stanley Martin ^a   Kwasny, Mary J ^a   Ahn, Joseph ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adherence; Hepatitis C; Specialty care pharmacy; Standard retail pharmacy; Sustained virologic response

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ERYTHROPOIETIN; PEGINTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ACUTE HEART INFARCTION; ADULT; AFRICAN AMERICAN; ARTICLE; BLURRED VISION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PATIENT CARE; PHARMACY; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMMUNITY PHARMACY SERVICES; ETHNIC GROUPS; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; INFECTIOUS DISEASE MEDICINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 60349125209     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L227     Document Type: Article

References (32)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(suppl 1):S30-4.
2. Bernstein B, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-82.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358: 958-65.
7. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
8. Davis GL, Wong JB, McHutchison JG, et al. Early virology response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
9. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat 2005;12:91-5.
10. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
11. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-51.
12. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9.
13. Flamm SL, Eshelman A, Lyons M, et al. Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alpha 2b (1.5//g/kg wk) + ribavirin (800-1400 mg/d): results of a prospective, randomized, controlled, multi-center trial (abstract #592). Hepatology 2002;36(suppl):311A.
14. Factors predicting patient compliance with specialty drug therapy for multiple sclerosis, inflammatory conditions, and hepatitis C. 2006.www.express-scripts.com/ourcompany/news/outcomesresearch/ onlinepublications/study/factorsPredictingPatientCompliance.pdf (accessed 2007 Dec 12).
15. Burton D, Shenouda S, Smith C, et al. Overview of a specialty pharmacy. 2004. www.express-scripts.com/ourcompany/news/industryreports/ specialtytrendreport/2004/overview.pdf (accessed 2007 Dec 12).
16. The frontier of specialty pharmacy care: an examination of primary disease states. 2005. www.pcmanet.org/research/pdf/SP-diseaseStates% 20FINAL100505.pdf (accessed 2007 Dec 12).
17. Caremark homepage. www.caremark.com (accessed 2007 Dec 12).
18. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005; 11(suppl):S296-306.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
20. McDonnell PJ, Jacobs MR. Hospital admission resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6. DOI 10.1345/aph.1A333
21. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoe AW, Leufkens HGM. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003;9: 404-11.
22. Malow RM, Baker SM, Klimas NG, et al. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv 1998;49:1021-4.
23. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000;12:399-404.
24. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22:738-47.
25. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23:209-16.
26. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
27. Cacoub P, Ouzan D, Fontanges T, et al. Patient education improves adherence to peginterferon alfa-2b and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life study (CHEOBS Study) (abstract #325). Hepatology 2007;46(suppl):384A.
28. Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy 2005; 25:1230-41.
29. Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health-Syst Pharm 2007;64:632-6.
30. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47.
31. Flamm SL, Goldman J, Nelligan G, et al. Improved adherence to pegylated interferon alpha 2b + ribavirin in academic centers vs community-based centers: results from a prospective, randomized, controlled, multicenter trial (abstract #297). Hepatology 2003;38(suppl):299A.
32. Conjeevarum HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7.